



## Correction to: Outcomes of hypercalcemia of malignancy in patients with solid cancer: a national inpatient analysis

Shruti Bhandari<sup>1</sup> · Rohit Kumar<sup>1</sup> · Prashant Tripathi<sup>2</sup> · Abigail Chan<sup>3</sup> · Sarah Mudra<sup>4</sup> · Rebecca Redman<sup>1</sup>

Published online: 1 November 2019  
© Springer Science+Business Media, LLC, part of Springer Nature 2019

**Correction to: Medical Oncology (2019) 36:90**  
<https://doi.org/10.1007/s12032-019-1315-8>

The original version of this article contains an error in the Tables 1 and 2. The correct version of Tables 1 and 2 were given below.

---

The original article can be found online at <https://doi.org/10.1007/s12032-019-1315-8>.

---

✉ Shruti Bhandari  
[shruti.bhandari@louisville.edu](mailto:shruti.bhandari@louisville.edu)

<sup>1</sup> Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville, 529 S Jackson St, Louisville, KY 40202, USA

<sup>2</sup> Division of Infectious Disease, University of Louisville, Louisville, KY 40202, USA

<sup>3</sup> Department of Medicine, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA

<sup>4</sup> School of Medicine, University of Louisville, Louisville, KY 40202, USA

**Table 1** Patient demographic and clinical characteristics

	No hypercalcemia <i>n</i> = 7,374,334	Hypercalcemia <i>n</i> = 126,875	<i>P</i> value
<i>Age, mean (years)</i>	65.7	65.7	0.95
<i>Female (%)</i>	48.9	49.3	0.26
<i>Race (%)</i>			<0.001
White	73.1	68.7	
Black	12.9	19.6	
Hispanic	7.8	6.7	
Other	6.1	5	
<i>Insurance (%)</i>			<0.001
Medicare	55.6	54.8	
Medicaid	10.2	14.4	
Private	28.9	24.5	
Other/self-pay	5.3	6.3	
<i>Total number of comorbidities, mean</i>	4.8	6	<0.001
<i>Hospital setting (%)</i>			<0.001
Rural	8.3	9.1	
Urban non-teaching	27.6	29.8	
Urban teaching	64	61.1	
<i>Hospital region (%)</i>			<0.001
Northeast	21.1	20.2	
Midwest	22.9	22.8	
South	37.6	39.6	
West	18.5	17.4	
<i>Type of cancer (%)</i>			
Lung	19.3	29.5	<0.001
Breast	8.7	10.3	<0.001
Colorectal/anal	11.7	3.8	<0.001
Prostate	9.6	3.9	<0.001
Head and neck	3.8	5.2	<0.001
Pancreatic	4.4	2.8	<0.001
Esophagus/gastric	3.6	2.7	<0.001
Liver/biliary tract	3.4	3	<0.001
Bone/connective tissue	1.9	1.3	<0.001
Melanoma	0.9	0.6	<0.001
Kidney/bladder	7.9	10.2	<0.001
Central nervous system	2.7	0.6	<0.001
Male genital	0.4	0.4	0.387
Female genital	6.6	4.8	<0.001
Other	16.9	22.8	<0.001
<i>Metastatic cancer (%)</i>	44	73.3	<0.001
<i>Mechanical ventilation use (%)</i>	3.6	4.7	<0.001
<i>Renal disease (%)</i>	10.5	14	<0.001
<i>Inpatient chemotherapy (%)</i>	3.8	4.8	<0.001
<i>Palliative consult (%)</i>	8.7	21.7	<0.001
<i>Protein calorie malnutrition (%)</i>	9.3	19.7	<0.001
<i>Total hospital charge (US dollars)</i>			<0.001
≤49K	63.7	61.4	
50–99K	22.1	22.4	
≥100K	14.2	16.2	

**Table 2** Predictors of mortality among patients hospitalized for hypercalcemia of malignancy

Characteristics and complications	Odds ratio (95% confidence interval)	<i>p</i> value
Age	1.01 (1.00,1.02)	<0.001
Sex (Female)	0.84 (0.77, 0.93)	0.001
Race		
White	Reference	
Black	0.89 (0.79, 1.00)	0.064
Hispanic	0.93 (0.77, 1.12)	0.498
Asian	1.21 (0.94, 1.57)	0.131
Other	1.14 (0.88, 1.47)	0.294
Insurance		
Medicare	Reference	
Medicaid	1.08 (0.93, 1.26)	0.272
Private	1.27 (1.13, 1.44)	<0.001
Self-pay/other	1.74 (1.46, 2.07)	<0.001
Charlson comorbidity index		
< 3	Reference	
≥ 3	1.06 (0.87, 1.29)	0.522
Type of facility		
Rural	Reference	
Urban non-teaching	0.84 (0.71, 0.99)	0.049
Urban teaching	0.89 (0.76, 1.04)	0.156
Metastatic disease	1.73 (1.52, 1.97)	<0.001
Protein calorie malnutrition	1.35 (1.22, 1.49)	<0.001
Inpatient chemotherapy	0.72 (0.58, 0.89)	0.003
Mechanical ventilation	12.07 (10.50, 13.87)	<0.001
Cardiopulmonary arrest	15.06 (8.62, 26.32)	<0.001

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.